OncoMatch/Clinical Trials/NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Is NCT06218914 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NT-112: Autologous, engineered T Cells targeting KRAS G12D and AZD0240: Autologous, engineered T Cells targeting KRAS G12D for non-small cell lung cancer.

Phase 1RecruitingAstraZenecaNCT06218914Data as of May 2026

Treatment: NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Colorectal Cancer

Pancreatic Cancer

Endometrial Cancer

Tumor Agnostic

Biomarker criteria

Required: KRAS G12D

Tumors must harbor a KRAS G12D variant mutation

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic standard of care treatment regimen

after at least 1 line of approved systemic standard of care (SOC) treatment regimen

Cannot have received: adoptive cell and gene therapy

History of prior adoptive cell and gene therapy

Cannot have received: allogeneic stem cell transplant

allogeneic stem cell transplant

Cannot have received: solid organ transplantation

solid organ transplantation

Cannot have received: pan-KRAS or KRAS G12D targeting agents

Exception: unless presence of KRAS G12D mutation is confirmed after the completion of treatment with pan-KRAS or KRAS G12D targeting agents

Prior treatment with pan-KRAS or KRAS G12D targeting agents unless presence of KRAS G12D mutation is confirmed after the completion of treatment with pan-KRAS or KRAS G12D targeting agents

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Duarte, California
Research Site · Los Angeles, California
Research Site · Newport Beach, California
Research Site · Jacksonville, Florida
Research Site · Chicago, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify